ACAD
ACADIA Pharmaceuticals Inc.
$21.20
+$0.09(+0.45%)
50
Overall
70
Value
20
Tech
60
Quality
Market Cap
$3.55B
Volume
567.46K
52W Range
$19.69 - $28.35
Target Price
$31.65
Order:
Income Statement
| Metric | Trend | Chart | 2016 Dec | 2017 Dec | 2018 Dec | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec | 2025 Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||||||
| Total Revenue | $17.3M | $124.9M | $223.8M | $339.1M | $441.8M | $484.1M | $517.2M | $726.4M | $957.8M | $1.1B | ||
| Total Revenue | $17.3M | $124.9M | $223.8M | $339.1M | $441.8M | $484.1M | $517.2M | $726.4M | $957.8M | $1.1B | ||
| COST OF GOODS SOLD | ||||||||||||
| Cost of Revenue | $-3.1M | $-9.1M | $-12.4M | $11.3M | $20.6M | $19.1M | $10.2M | $41.6M | $81.8M | $89.0M | ||
| GROSS PROFIT | ||||||||||||
| Gross Profit | $12.9M | $-13.1M | $205.5M | $327.7M | $421.2M | $465.0M | $507.1M | $684.8M | $876.0M | $982.5M | ||
| OPERATING EXPENSES | ||||||||||||
| Operating Expenses | $285.7M | $404.3M | $452.9M | $566.0M | $707.8M | $635.4M | $730.7M | $758.2M | $791.7M | $877.7M | ||
| Research & Development | $99.3M | $149.2M | $187.2M | $240.4M | $319.1M | $239.4M | $361.6M | $351.6M | $303.2M | $328.8M | ||
| Research Expense | $99.3M | $149.2M | $187.2M | $240.4M | $319.1M | $239.4M | $361.6M | $351.6M | $303.2M | $328.8M | ||
| Selling, General & Administrative | $186.5M | $255.1M | $265.8M | $325.6M | $388.7M | $396.0M | $369.1M | $406.6M | $488.4M | $548.9M | ||
| Selling & Marketing Expenses | $186.5M | $255.1M | $265.8M | $38.3M | $51.1M | $1.8M | $5.5M | $9.4M | $21.1M | -- | ||
| General & Administrative Expenses | $-2.8M | $-3.8M | $-4.5M | $325.6M | $388.7M | $396.0M | $369.1M | $406.6M | $488.4M | $548.9M | ||
| Promotion & Advertising | $-1.6M | $-15.6M | $-39.8M | $38.3M | $51.1M | $1.8M | $5.5M | -- | -- | -- | ||
| Salaries & Wages | $-55.3M | $-75.5M | $-81.6M | -- | -- | $600.0K | $68.2M | -- | -- | -- | ||
| Depreciation & Amortization | $-843.0K | $-1.2M | $-1.5M | $1.3M | $1.5M | $2.2M | $2.0M | $1.5M | $900.0K | -- | ||
| Depreciation & Amortization | $-843.0K | $-1.2M | $-1.5M | $1.3M | $1.5M | $2.2M | $2.0M | -- | -- | -- | ||
| Amortization | $-985.0K | $-1.5M | $-1.5M | $1.5M | $1.5M | $1.1M | -- | $4.1M | $15.0M | -- | ||
| Other Operating Expenses | $-363.0K | $-361.0K | $-4.5M | $-1.9M | $-2.7M | $-4.0M | $-5.1M | -- | -- | -- | ||
| OPERATING INCOME | ||||||||||||
| Operating income | $-272.8M | $-417.3M | $-247.4M | $-246.5M | $-286.6M | $-170.4M | $-223.6M | $-73.4M | $230.8M | $104.8M | ||
| EBITDA | $-268.1M | $-285.9M | $-241.5M | $-235.2M | $-283.7M | $-167.1M | $-211.4M | $-62.7M | $248.5M | $119.0M | ||
| NON-OPERATING ITEMS | ||||||||||||
| Interest Expense (Non-Operating) | -- | -- | -- | -- | -- | -- | -- | $-17.2M | $-25.5M | $-31.7M | ||
| Intinc | $2.8M | $4.1M | $5.3M | $11.2M | $6.6M | $591.0K | $6.6M | -- | -- | -- | ||
| Net Non-Operating Interest Income/Expense | $2.8M | $4.1M | $5.3M | $11.2M | $6.6M | $591.0K | $6.6M | $17.2M | $25.5M | $31.7M | ||
| Gain on Sale of Securities | -- | -- | $-1.8M | $997.0K | $-997.0K | $2.3M | $3.5M | -- | -- | -- | ||
| Other Income/Expense | -- | $-124.9M | $1.8M | $-997.0K | $997.0K | $-2.3M | $3.5M | $-5.1M | $-148.3M | $-2.4M | ||
| Other Special Charges | -- | $124.9M | $-1.8M | $997.0K | $-997.0K | $2.3M | $3.5M | $5.1M | $148.3M | $2.4M | ||
| PRE-TAX INCOME | ||||||||||||
| EBIT | $-270.1M | $-288.3M | $-243.9M | $-234.4M | $-286.6M | $-170.4M | $-213.4M | $-68.3M | $232.6M | $107.2M | ||
| Pre-Tax Income | $-270.1M | $-288.3M | $-243.9M | $-234.4M | $-281.0M | $-167.5M | $-213.4M | $-51.0M | $258.1M | $138.9M | ||
| INCOME TAX | ||||||||||||
| Tax Provision | $1.3M | $1.1M | $1.3M | $876.0K | $611.0K | $351.0K | $2.5M | $10.3M | $31.6M | $-252.1M | ||
| NET INCOME | ||||||||||||
| Net Income | $-271.4M | $-289.4M | $-245.2M | $-235.3M | $-281.6M | $-167.9M | $-216.0M | $-61.3M | $226.5M | $391.0M | ||
| Net Income (Continuing Operations) | $-271.4M | $-289.4M | $-245.2M | $-235.3M | $-281.6M | $-167.9M | $-216.0M | $-61.3M | $226.5M | $391.0M | ||
| Net Income (Discontinued Operations) | $-271.4M | $-289.4M | $-245.2M | $-235.3M | $-281.6M | $-167.9M | $-216.0M | $-61.3M | $226.5M | $391.0M | ||
| Net Income (Common Stockholders) | $-271.4M | $-289.4M | $-245.2M | $-218.8M | $-281.6M | $-167.9M | $-216.0M | $-61.3M | $226.5M | $391.0M | ||
| Normalized Income | -- | -- | -- | -- | -- | -- | -- | -- | -- | $-113.2M | ||
| TOTALS | ||||||||||||
| Total Expenses | $282.7M | $395.2M | $440.5M | $577.4M | $718.0M | $646.3M | $740.8M | $799.8M | $873.5M | $966.7M | ||
| SHARE & EPS DATA | ||||||||||||
| Average Shares Outstanding | $115.9M | $122.6M | $126.6M | $147.2M | $157.3M | $160.5M | $161.7K | $163.8K | $165.7M | $168.4M | ||
| Average Shares Outstanding (Diluted) | $116.0M | $122.6M | $126.4M | $147.2M | $157.3M | $160.5M | $161.7K | $163.8K | $166.4M | $169.9M | ||
| Shares Outstanding | $121.4M | $124.7M | $143.9M | $155.3M | $160.0M | $161.2M | $162.2M | $164.8M | $166.8M | $170.5M | ||
| Basic EPS | -- | -- | -- | $-1.6 | $-1.79 | $-1.05 | $-1.34 | $-0.37 | $1.37 | $2.32 | ||
| Basic EPS (Continuing Operations) | -- | -- | -- | $-1.6 | $-1.79 | $-1.05 | $-1.34 | $-0.37 | $1.37 | $2.32 | ||
| Diluted EPS | $-2.34 | $-2.36 | $-1.94 | $-1.6 | $-1.79 | $-1.05 | $-1.34 | $-0.37 | $1.36 | $2.3 | ||
| Diluted EPS (Continuing Operations) | -- | -- | -- | -- | -- | -- | $-1.34 | $-0.37 | $1.36 | $2.3 | ||
| OTHER METRICS | ||||||||||||
| Earnings from equity interest | -- | -- | -- | -- | $-281.0M | $-167.5M | $-213.4M | -- | -- | -- | ||
| Earnings From Equity Interest Net Of Tax | -- | -- | -- | -- | $-281.0M | $-167.5M | $-213.4M | -- | -- | -- | ||
| Gain On Sale Of P P E | -- | -- | -- | $200.0K | $3.1M | -- | $100.0K | -- | -- | -- | ||
| Net Income Discontinuous Operations | $200.0K | $400.0K | $1.6M | -- | -- | -- | -- | -- | -- | -- | ||
| Other Gand A | $-2.8M | $-3.8M | $-4.5M | $325.6M | $388.7M | $396.0M | $369.1M | $406.6M | $488.4M | $548.9M | ||
| Other Write Off | -- | -- | $-100.0K | -- | -- | -- | -- | -- | -- | -- | ||
| Provision For Gain Loss On Disposal | $200.0K | $400.0K | $1.6M | -- | -- | -- | -- | -- | -- | -- | ||
| Rent And Landing Fees | $-2.8M | $-3.8M | $-4.5M | -- | -- | -- | -- | -- | -- | -- | ||
| Selling Expense | $186.5M | $255.1M | $265.8M | -- | -- | -- | -- | -- | -- | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | ACAD | $21.20 | +0.5% | 567.46K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get ACADIA Pharmaceuticals Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW